Janney Montgomery Scott LLC Has $2.82 Million Position in Edwards Lifesciences Co. (NYSE:EW)

Janney Montgomery Scott LLC reduced its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 28.3% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 42,793 shares of the medical research company’s stock after selling 16,873 shares during the quarter. Janney Montgomery Scott LLC’s holdings in Edwards Lifesciences were worth $2,824,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in EW. Crewe Advisors LLC acquired a new stake in Edwards Lifesciences in the first quarter valued at approximately $28,000. First Community Trust NA acquired a new stake in Edwards Lifesciences in the second quarter valued at approximately $29,000. Webster Bank N. A. acquired a new stake in Edwards Lifesciences in the second quarter valued at approximately $39,000. Versant Capital Management Inc lifted its stake in Edwards Lifesciences by 206.3% in the second quarter. Versant Capital Management Inc now owns 484 shares of the medical research company’s stock valued at $45,000 after acquiring an additional 326 shares during the last quarter. Finally, HHM Wealth Advisors LLC acquired a new stake in Edwards Lifesciences in the second quarter valued at approximately $55,000. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Edwards Lifesciences Trading Up 0.7 %

NYSE EW opened at $66.70 on Tuesday. The company has a market cap of $39.34 billion, a PE ratio of 9.56, a PEG ratio of 3.72 and a beta of 1.12. The company has a current ratio of 3.46, a quick ratio of 2.87 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Co. has a 12 month low of $58.93 and a 12 month high of $96.12. The stock has a 50 day moving average of $67.59 and a 200-day moving average of $76.80.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.67. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. The business had revenue of $1.35 billion for the quarter, compared to analysts’ expectations of $1.57 billion. During the same quarter in the prior year, the business earned $0.59 EPS. The firm’s revenue for the quarter was up 8.9% on a year-over-year basis. On average, equities research analysts anticipate that Edwards Lifesciences Co. will post 2.57 EPS for the current fiscal year.

Insider Activity at Edwards Lifesciences

In related news, insider Larry L. Wood sold 25,000 shares of the stock in a transaction on Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total value of $1,647,750.00. Following the sale, the insider now owns 198,526 shares in the company, valued at approximately $13,084,848.66. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Edwards Lifesciences news, insider Larry L. Wood sold 25,000 shares of the stock in a transaction on Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the transaction, the insider now owns 198,526 shares in the company, valued at $13,084,848.66. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Daveen Chopra sold 1,250 shares of the stock in a transaction on Tuesday, August 20th. The stock was sold at an average price of $69.95, for a total value of $87,437.50. Following the transaction, the vice president now owns 29,333 shares in the company, valued at $2,051,843.35. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 41,250 shares of company stock worth $2,746,988. Company insiders own 1.29% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on EW shares. Wells Fargo & Company reduced their target price on shares of Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating for the company in a research note on Monday, September 9th. Jefferies Financial Group lowered shares of Edwards Lifesciences from a “buy” rating to a “hold” rating and dropped their price target for the company from $85.00 to $70.00 in a research report on Wednesday, September 18th. Royal Bank of Canada dropped their price target on shares of Edwards Lifesciences from $85.00 to $75.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 8th. Bank of America lowered shares of Edwards Lifesciences from a “buy” rating to a “neutral” rating and dropped their price target for the company from $105.00 to $75.00 in a research report on Thursday, July 25th. Finally, Wolfe Research raised shares of Edwards Lifesciences from an “underperform” rating to a “peer perform” rating in a research report on Monday, July 29th. Seventeen research analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $75.67.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.